Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.
Svetlana Blitshteyn, Jill R Schofield, Nichole Haire et al.
✦ AI-curated · Sources linked
Case in brief
A 42-year-old woman developed vasovagal syncope (VVS) and neuropathic leg pain after COVID-19 mRNA vaccination. Following semaglutide treatment, her COMPASS-31 score decreased by 44% and her Orthostatic Hypotension Questionnaire score by 59%; average 24-hour heart rate fell from 97 beats per minute (bpm) to 80 bpm. Her leg pain also completely resolved. The report describes substantial improvement in autonomic symptoms and neuropathic pain in this individual, but does not establish that semaglutide caused the improvement.
What made this case unusual
The report describes improvement of post-vaccination VVS and complete resolution of associated neuropathic leg pain during treatment with a GLP-1 receptor agonist, an approach the authors suggest warrants further study.
Diagnostic / clinical pearl
In this case, symptom scores and 24-hour heart rate improved alongside resolution of neuropathic pain during semaglutide treatment; a single case cannot establish treatment efficacy.
Why it matters
The authors propose GLP-1 receptor agonists as candidates for randomized placebo-controlled trials in patients with post-vaccination dysautonomia and neuropathic pain.